Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHONQUER: phase 3 ivosidenib versus placebo in IDH1-mutant advanced conventional chondrosarcoma
CTR20251421Phase 3Active
- Sponsor
- Servier
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ivosidenib in chondrosarcoma, sponsored by Servier. Started Jun 2025; status: active.
02
Drugs
ivosidenib
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on CTR20251421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251421.